未来人工晶状体技术
本文综述了人工晶状体(IOL)技术的未来发展方向,涵盖可调节/可精细调整的人工晶状体、老视矫正(扩展景深IOL、针孔IOL)、可调节IOL及用于青光眼管理的眼内压微型传感器。最新一代(2.0)光可调晶状体(RxSight)已进入临床实践且初步结果令人鼓舞。IOL技术将持续推动眼科发展,其影响远超白内障手术。
要点
- 最新一代(2.0)光可调晶状体已进入临床实践,初步结果令人鼓舞。
- 针孔IOL除屈光矫正外,对虹膜缺损和不规则角膜有治疗潜力。
- Eyemate眼内压传感器可在小切口白内障手术中植入,有望革新青光眼管理。
核心结论
- 人工晶状体技术将持续推动眼科发展,其积极影响远超白内障手术。
- 术后屈光力可调整将实现个性化精细调整,帮助患者获得预期视力并尽可能摆脱眼镜依赖。
- 眼内压微型传感器是IOL技术影响超越白内障手术的重要例证。
研究设计与样本
- 本文为综述,总结近期IOL技术创新及未来发展方向。
主要发现
- 最新一代(2.0)光可调晶状体(RxSight)已进入临床实践,初步结果令人鼓舞。
- 其他改变已植入IOL屈光力的方法正在开发中。
- 扩展景深IOL和针孔IOL技术已推出;针孔IOL对虹膜缺损和不规则角膜已有帮助。
- 多种可调节IOL技术正在测试中:一种利用睫状肌剩余力量,另一种由远近视切换时的瞳孔反应触发。
- Eyemate眼内压传感器在小切口白内障手术中植入,更新一代更小型传感器将经脉络膜上腔植入,未来将成为囊环的一部分。
关键数值与推荐
- 最新一代(2.0)光可调晶状体(RxSight)已进入临床实践。
- Eyemate(Implandata Ophthalmics Products GmbH)为最新一代眼内压传感器,在小切口白内障手术中植入。
- 更新一代更小型眼内压传感器将经脉络膜上腔植入,未来将成为囊环的一部分。
临床怎么用
- 光可调晶状体可用于术后屈光力精细调整,实现个性化视力并提高脱镜率。
- 针孔IOL可用于虹膜缺损和不规则角膜的屈光矫正与治疗。
- 眼内压传感器可在白内障手术中植入,实现 habitual 眼内压的持续测量,助力青光眼管理。
局限性
- 光可调晶状体以外改变已植入IOL屈光力的方法尚在开发中。
- 可调节IOL技术仍在测试阶段。
- 更小型经脉络膜上腔植入及囊环形式的眼内压传感器尚属未来发展方向。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The future of intraocular lens (IOL) technology has already begun with a number of recent innovations. The postoperative change of refractive power will lead to a customized fine-tuning that provides patients with the individual vision they expect and with as much spectacle independence as possible. The latest-generation (2.0) Light-Adjustable Lens (RxSight) was recently introduced into clinical practice, with the first results being very encouraging. Other methods of altering the power of an already implanted IOL are under development. The same can be said about the correction of presbyopia, the so-called last frontier in refractive surgery. Extended depth-of-focus IOLs have been introduced, as has the technology of the pinhole IOL. The latter has therapeutic potential beyond the refractive aspect and has already proven helpful in cases of iris defects and irregular corneas. Several technologies are currently being tested to achieve-finally-an accommodative IOL. One such concept uses the (remaining) strength of the ciliary muscle, whereas another is triggered by the pupil reaction when shifting focus from far to near. Not an IOL itself, but rather a high-tech innovation that so far has mostly been implanted during cataract surgery, is a microelectronic sensor that measures habitual intraocular pressure (IOP) at any given time and promises to revolutionize the management of glaucoma patients. The last generation of this device (Eyemate; Implandata Opthalmics Products GmbH) is implanted during small-incision cataract surgery; the latest development is an even smaller sensor that will be inserted suprachoroidally before, in the near future, such a device will be part of a capsular ring. These IOP sensors are a prime example that IOL technology will continue to be a driving force in ophthalmology, with a positive impact far beyond cataract surgery.
引用
- Dick HB, Gerste RD. Future Intraocular Lens Technologies. Ophthalmology. 2020. PMID: 33373617. doi:10.1016/j.ophtha.2020.12.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。